Canada: CIPO Issues Revised Examination Guidance On Methods Of Medical Treatment And Dosage Regimens


The Canadian Intellectual Property Office (CIPO) has now released Practice Notice PN 2015-01, which relates to examination of medical treatment claims. The Practice Notice softens some of the current examination guidelines on the patentability of dosage regimens. In this new guidance, essential claim elements which relate to a fixed dosage, a fixed dosage regimen, a patient sub-population, or to an administration site are now identified as elements which are not considered to limit a physician's professional skill or judgment, an important factor in determining subject matter eligibility.


On March 18, 2015, the Canadian Intellectual Property Office (CIPO) released Practice Notice PN 2015-01 – "Revised Examination Practice Respecting Medical Uses", which revises previous Practice Notice PN 2013-04 (June, 2013; discussed in further detail here) regarding the examination of medical and surgical method claims in Canada. PN 2015-01 is intended to update CIPO's examination practice concerning medical use claims following a recent Federal Court decision in AbbVie Biotechnology Ltd. v. The Attorney General of Canada, 2014 FC 1251 ("AbbVie").

The updated Practice Notice softens examination guidelines concerning the patentability of medical use claims, particularly claims to dosage regimens. While it remains to be seen exactly how CIPO will implement this guidance moving forward, the revisions strongly imply that fixed dosage regimens will not be automatically considered impermissible subject matter so long as the essential elements of the claims do not prevent, interfere with, or require the professional skill of a physician.

Revised Practice Notice PN 2015-01 and  Methods of Medical Treatment

In Canada, medical use claims are generally considered patent-eligible subject matter, whereas methods of medical treatment are not. The revised notice maintains that inventions which prevent physicians "from exercising their skill and judgment in using a known compound for an established purpose" cover a method of medical treatment and therefore are non-statutory subject matter; however, additional guidance is now provided regarding whether or not essential claim elements relating to dosage regimens should be interpreted as skill- or judgment-limiting to the physician.

The previous Practice Notice (PN 2013-04) noted that:

"if, however, it is determined after a purposive construction that a dosage regimen or dosage range is an essential element of a claim encompassing the use of a known compound in an established treatment, then the claim covers a method of medical treatment, and thus, is not compliant with section 2 of the Patent Act".

This statement has been softened in the revised Practice Notice, which now indicates that:

"if it is determined after a purposive construction that a dosage range, or dosage regimen that includes a range, is an essential element of a claim encompassing the use of a known compound in an established treatment, then the claim may cover a method of medical treatment". (emphasis added)

As well, the previous Practice Notice PN 2013-04 indicated that:

"where an essential element only serves to instruct a medical professional "how" to treat a patient, rather than "what" to use to treat the patient, this will lead to the conclusion that the claimed use encompasses a method of medical treatment".

The revised Practice Notice has been updated to clarify that:

"where an essential element only serves to instruct a medical professional "how" to treat a patient, rather than "what" to use to treat the patient, it must be determined whether the essential element prevents, interferes with or requires the professional skill of a physician. If the answer is "yes", this will lead to the conclusion that the claimed use encompasses a method of medical treatment that does not comply with section 2 of the Patent Act". (emphasis added)

One of the most important revisions in PN 2015-01 appears in the section of PN 2013-04 which elaborates on examples of essential claim elements which limit a physician's professional skill or judgment. PN 2013-04 recited that:

"essential elements that point to a limitation of a physician's professional skill or judgment include those that provide details of a dosing schedule, those that represent a range of potential dosages that a patient may receive (as distinct from a range of dosage forms), and those that narrow treatment to a patient sub-population (rather than bring treatment to a new population) or administration site".

The revised section, however, now recites that:

"essential elements that point to a limitation of a physician's professional skill or judgment include those that provide details of a dosing schedule encompassing a range and those that represent a range of potential dosages that a patient may receive (as distinct from a range of dosage forms). In contrast, essential elements that narrow treatment to a fixed dosage, a fixed dosage regimen, a patient sub-population or to a particular administration site are not considered to point to a limitation of a physician's professional skill or judgment".

These amendments should guide patent Examiners away from issuing objections to claims encompassing dosage regimens without first considering how the claims relate to the physician's professional skill and judgment. Importantly, claims which encompass a fixed dosage or dosage regimen, as opposed to a dosage or dosage regimen range, appear to be specifically identified as patent-eligible subject matter. Indeed, in AbbVie, it was noted at paragraph 114 that "... a claim which does not restrict, or interfere with, or otherwise engage professional skill or judgment – including a claim for a fixed dosage and or a fixed dosage schedule or interval – is not impermissible subject matter where there is no evidence to contradict that claimed dosage". 

Furthermore, the revised Practice Notice now specifies that essential claim elements which narrow treatment to a patient sub-population or to a particular administration site are no longer considered to limit a physician's professional skill or judgment. These revisions should be of particular interest to those operating in the personalized medicine field, where the identification of patient sub-populations may often be of special importance.


Revised Practice Notice PN 2015-01 will come as a welcome change for many companies operating in the life sciences area. While methods of medical treatment remain outside the scope of "invention", this revised Practice Notice opens the possibility for claims encompassing inventions which include fixed dosage regimens, patient sub-populations, or particular administration sites as essential elements, so long as they do not prevent, interfere with or require the professional skill of a physician. Generally speaking, CIPO has long viewed claims concerning "what" to use for treatment (i.e. compounds or compositions) as patent eligible. With this revision, it appears CIPO is now also willing to consider claims concerning "how" to treat a patient, so long as the physician's skill and judgment is not engaged.

It remains to be seen how CIPO will implement the guidance provided in PN 2015-01 moving forward. The revised Practice Notice maintains that dosage regimens encompassing ranges rather than a fixed dosage or interval are still likely to be considered as methods of medical treatment by CIPO and therefore unpatentable subject matter. However, these recent developments indicate a softening of CIPO's position concerning the patentability of dosage regimens, and will likely come as a welcome shift in perspective for many in the pharmaceutical industry.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.